Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics, including programs targeting HER2 and other oncology and immunology indications. The company reached the public markets through a SPAC business combination and was an active filer as of its 10-Q submission on November 10, 2022, covering its operations as a combined public entity. The filing, accession number 0001193125-22-282585, reflects the company's post-merger reporting obligations under SEC requirements. Abpro operates within the biotechnology and clinical-stage drug development sector. For complete filing history, deal terms, and pipeline data on Abpro Holdings and thousands of other SPAC-linked companies, sign up for full access at SpacDesk.